Geleol Mono and Diglycerides NF

Maisine® CC (glyceryl monolinoleate) is an oil composed of long-chain mono-, di-, and triglycerides for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble lipophilic APIs. Used in self-emulsifying lipid formulations (SEDDS and SMEDDS) as an oily vehicle. Its hi...

Compritol® 888 ATO (glyceryl dibehenate) is a glyceride with a high melting point used as a modified release agent or lubricant in tablets. Can also be used in lipid coating technologies and as lipid carrier for nanoparticles.

Compritol® 888 Pellets (glyceryl dibehenate) is a glyceride with a high melting point used as consistency agent in topical formulations.

Compritol® E ATO (for nutraceuticals) is a high melting point lipid obtained by the esterification of glycerin with C22 fatty acid, conforming to food additive status. The powder form is used as a modified release agent or lubricant for high-dose nutraceutical tablets.
PALM OIL FREE version a...

Compritol® HD5 ATO (behenoyl polyoxyl-8 glycérides) is a glyceride with an intermediate melting point containing PEG-8 esters. A powder wetting agent and lubricant for effervescent and fast-dissolving tablets.

Emulcire 61WL 2659 is a non-ionic oil-in-water emulsifier for use in association with Gelot 64 as a co-emulsifier to improve heat stability in creams. It is available in semi solid pellets form.

Geloil SC is a mixture of refined soybean oil USP-NF, glyceryl distearate USP-NF and polyglyceryl-3 dioleate USP-NF. A thixotropic suspension vehicle for nutraceutical and pharmaceutical APIs. Ready-to-use in a cold process for thermosensitive actives in soft gel capsule.

Gelot™ 64 is a nonionic oil-in-water emulsifier for topical emulsions. It provides excellent emulsion stability with difficult-to-formulate and combination APIs. Provides heat stability and high tolerance over a wide pH range.

Gelucire® 48/16 Pellets is a non-ionic pure surfactant for lipid-based formulation to solubilize and increase oral bioavailability of poorly soluble API. Forms micellar solution in aqueous media.

Gelucire® 43/01 is a glyceride with an intermediate melting point used as a matrix agent for sensitive APIs and a viscosity-increasing agent in oral and topical formulations.

Gelucire® 44/14 (lauroyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS).

Gelucire® 50/13 (stearoyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS).

Discover Gelucire® 59/14, an add-on in Gattefossé Gelucire® range, for oral bioavailability enhancement

Selecting best excipient

Discover Labrafac™ MC60, glycerol monocaprylocaprate, an oral bioavailability enhancer.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. Patient adherence to skin treatments Bi-gels: formulating new topical drugs Emulfree® Duo, a ready-to-use excipient designed to make bi-gels Case studies

Discover our brand new excipient Emulfree® Duo, a ready-to-use stabilizing agent, enabler of bi-gel, an emerging topical dosage form.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. This session explores: Using Lipid-based formulations to address oral bioavailability issues Labrafac™ MC60, glycerol monocaprylocaprate, Gattefossé new bioehancer Case study: step-by-step development of a lipid-based formulation of dutasteride with Labrafac™ MC60 Gattefossé technical expertise

Many drugs exhibit poor solubility and/or permeability leading to weak oral bioavailability. To overcome these issues, different technologies have been developed. Among them, lipid-based formulation (LBF) is an option worth considering as it can be used from the very beginning of drug development to product, reducing time to market.